AngioDynamics gets nod for Morpheus

AngioDynamics has received Food and Drug Administration 510(k) clearance for its Morpheus CT peripherally inserted central catheter (PICC).

Morpheus is constructed of Durathane, a biocompatible and durable material that offers increased stiffness on the proximal end for ease of placement, a softer distal end for patient comfort, and simplified site care, according to the Queensbury, NY-based company, a majority-owned subsidiary of E-Z-EM.

Indicated for use with CT injectors, Morpheus will allow physicians to utilize the existing PICC for both medications and CT imaging, avoiding the need for an additional access site, according to the vendor. AngioDynamics expects to begin marketing Morpheus in the U.S. in September.

By staff writers
July 29, 2004

Related Reading

E-Z-EM shifts barium manufacturing, June 9, 2004

AngioDynamics prices IPO, May 28, 2004

AngioDynamics unveils Morpheus, April 15, 2004

E-Z-EM turns in record Q3, April 8, 2004

E-Z-EM sponsors VC CME, March 11, 2004

Copyright © 2004

Page 1 of 655
Next Page